JPMorgan initiates coverage of Nektar at 'underweight'
An analyst from JPMorgan initiated coverage of Nektar (NASDAQ: NKTR) at 'underweight' . Prior to this rating, Nektar had 1 buy ratings, 4 hold ratings, and 0 sell ratings. For consensus...
Neutral
or
Nektar News & Analysis
-
-
TD Cowen upgrades Nektar to 'outperform'
An analyst from TD Cowen upgraded Nektar (NASDAQ: NKTR) from 'market perform' to 'outperform' . Prior to this rating, Nektar had 0 buy ratings, 6 hold ratings, and 0 sell ratings. For...
-
Mizuho Securities maintains Nektar at 'neutral' with a price target of $5.0000
An analyst from Mizuho Securities maintained Nektar (NASDAQ: NKTR) at 'neutral' with a price target of $5.0000 from a prior price target of $6.0000. Prior to this rating, Nektar had 0 buy...
-
Nektar earnings beat by $0.01, revenue topped estimates
Investing.com - Nektar (NASDAQ: NKTR) reported third quarter EPS of $-0.1900, $0.01 better than the analyst estimate of $-0.2000. Revenue for the quarter came in at $24.1M versus the...
-
Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin
Nektar Therapeutics (NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, in patients with atopic dermatitis (AD) at...
-
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group to Evaluate NKTR-255
Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. ("CBMG"). The study will evaluate...
-
Nektar Therapeutics Reports Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics (Nasdaq: NKTR) today announced new data for rezpegaldesleukin in patients with atopic dermatitis, including new clinical efficacy endpoints from the Phase 1b study....
-
Nektar earnings beat by $0.01, revenue fell short of estimates
Investing.com - Nektar (NASDAQ: NKTR) reported second quarter EPS of $-0.2700, $0.01 better than the analyst estimate of $-0.2800. Revenue for the quarter came in at $20.5M versus the...
-
Nektar Therapeutics Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data
Nektar Therapeutics (Nasdaq: NASDAQ:NKTR) today announced that efficacy data previously generated by Eli Lilly & Company for rezpegaldesleukin (REZPEG) that were presented at the...
-
Jefferies upgrades Nektar to 'hold' with a price target of $1.00
An analyst from Jefferies upgraded Nektar (NASDAQ: NKTR) from Underperform 'hold' with a price target of $1.00 from a prior price target of $1.50. Prior to this rating, Nektar had 0 buy...
-
Nektar earnings beat by $0.97, revenue topped estimates
Investing.com - Nektar (NASDAQ: NKTR) reported first quarter EPS of $0.73, $0.97 better than the analyst estimate of $-0.24. Revenue for the quarter came in at $21.6M versus the consensus...
-
Nektar Therapeutics to Regain Full Rights to Rezpegaldesleukin
Nektar Therapeutics (Nasdaq: NASDAQ:NKTR) today announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company.As announced in a press release issued on April...
-
Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan
Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs -- -- Development of NKTR-255 in diffuse large B-cell lymphoma and bladder...
-
Nektar Therapeutics Dropped from S&P SmallCap 600
Crane Co. (CR) will be added to the S&P MidCap 400 effective prior to the open of trading on Tuesday, April 4, replacing PacWest Bancorp (PACW) which will be moved to the S&P SmallCap 600...
-
Crane to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600
Crane Co. (CR) will be added to the S&P MidCap 400 effective prior to the open of trading on Tuesday, April 4, replacing PacWest Bancorp (PACW) which will be moved to the S&P SmallCap 600...
-
Nektar Therapeutics Has No Exposure to Silicon Valley Bank
Nektar Therapeutics (Nasdaq: NASDAQ:NKTR) today issued a statement confirming that it does not have any accounts at Silicon Valley Bank, and it does not hold any cash deposits or...
-
Nektar earnings beat by $0.13, revenue fell short of estimates
Investing.com - Nektar (NASDAQ: NKTR) reported fourth quarter EPS of $-0.32, $0.13 better than the analyst estimate of $-0.45. Revenue for the quarter came in at $22.02M versus the consensus...
-
After-hours movers: Beyond Meat gains on EPS, Adobe falls as DoJ may sue to block Figma deal
After-Hours Movers: Nektar Therapeutics (NASDAQ:NKTR) 33% LOWER; says primary endpoint was not met in Phase 2 topline study for Rezpegaldesleukin in patients with Systemic Lupus...
-
Nektar Therapeutics to Resume Trading at 5 p.m.
Nektar Therapeutics (NKTR) to Resume Trading at 5 p.m.
-
Nektar Therapeutics Reports Phase 2 Topline Data for Rezpegaldesleukin
Nektar Therapeutics (Nasdaq: NASDAQ:NKTR) today announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of rezpegaldesleukin (also known as LY3471851 or...
-
Nektar Therapeutics Halted, News Pending
Nektar Therapeutics (NKTR) Halted, News Pending
-
Nektar Therapeutics Tops Q2 EPS by 9c
Nektar Therapeutics (NASDAQ:NKTR) reported Q2 EPS of ($0.85), $0.09 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $21.6 million versus the consensus...
-
Nektar Stock Crashes 33% After Stopping Clinical Trials for Key Cancer Drug, Goldman Sachs Downgrades to Sell
Shares of Nektar Therapeutics (NASDAQ:NKTR) are down over 33% in pre-open Monday after the company said it stopped all trials involving its key cancer drug after it had failed to yield...
-
Pre-Open Stock Movers 04/18: Casa Systems and Natus Medical Higher; TG Therapeutics and Nektar Lower (more...)
Pre-Open Stock Movers: Casa Systems , Inc. (Nasdaq: NASDAQ:CASA) 47% HIGHER; awarded a multi-year purchase contract from Verizon (NYSE:VZ) and Verizon will take a 9.9% stake. TG...
-
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.00%
Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Financials, Healthcare and Utilities sectors propelled shares higher while losses in the Oil & Gas,...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.87%
Investing.com – U.S. equities were higher at the close on Monday, as gains in the Consumer Services, Utilities and Basic Materials sectors propelled shares higher. At the close in NYSE, the...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.86%
Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Telecoms, Utilities and Basic Materials sectors propelled shares lower. At the close in NYSE, the Dow...
-
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.17%
Investing.com – U.S. equities were mixed at the close on Thursday, as gains in the Consumer Services, Technology and Healthcare sectors propelled shares higher while losses in the Telecoms,...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.56%
Investing.com – U.S. equities were higher at the close on Friday, as gains in the Oil & Gas, Consumer Services and Basic Materials sectors propelled shares higher. At the close in NYSE, the...
-
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.10%
Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Technology, Consumer Services and Consumer Goods sectors propelled shares higher while losses in the...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.30%
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Utilities, Technology and Industrials sectors propelled shares higher. At the close in NYSE, the Dow...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.92%
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Technology, Industrials and Financials sectors propelled shares higher. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
